At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,724 enrolled
Drug / intervention
Minocycline hydrochloride capsule +1 moredrug
Likely dose
Minocycline hydrochloride capsule 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke: A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase III Trial
In Brief
A Phase 3 clinical trial evaluating Minocycline hydrochloride capsule and Placebo capsules of Minocycline hydrochloride capsules for Ischemic Stroke, Acute. Completed, enrolled 1,724 participants across 58 sites.
Detailed Summary
The aim of this study was to evaluate the efficacy and safety of Minocycline versus placebo in the treatment of patients with moderate to severe acute ischemic stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, Acute
CountriesChina
CollaboratorsNeurodawn Pharmaceutical Co., Ltd.
Timeline
Phase 3CompletedFinished
202420252026
First PostedMay 2023
Enrollment StartMay 2023
Primary CompletionMay 2024
Study CompletionAug 2024
TodayJul 2026
First PostedMay 1, 2023
Enrollment StartMay 19, 2023
Primary CompletionMay 20, 2024
Study CompletionAug 15, 2024
TodayJul 1, 2026
Enrollment to primary: 1.0 yearsPosted 3.2 years ago
Interventions
Minocycline hydrochloride capsuledrug
50 mg per capsule, containing 50mg of Minocycline Hydrochloride.
Placebo capsules of Minocycline hydrochloride capsulesdrug
50 mg per capsule, containing 0mg of Minocycline Hydrochloride.